MajesTEC-1: Efficacy and Safety of Teclistamab
Experts on multiple myeloma review the study design and results from MajesTEC-1, focusing on the efficacy and safety findings, and provide insights on adverse event management practices.
EP: 1.The Current Treatment Landscape for Relapsed/Refractory Multiple Myeloma
Now Viewing
EP: 2.MajesTEC-1: Efficacy and Safety of Teclistamab
EP: 3.Teclistamab Dosing and Adverse Event Prophylaxis Practices
EP: 4.Clinical Implications of MajesTEC-1
EP: 5.Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma
Video content above is prompted by the following question:
- What were the efficacy and safety findings from the long-term follow-up from MajesTEC-1?
Recent Videos
Related Content
Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma
December 26th 2024Article
Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.
